Claims
- 1. A method for reducing elevated blood pressure in a mammal having high blood pressure and in need of treatment which comprises administering to said mammal a hypotensive dose of a drug of the formula ##STR13## wherein one of R and R.sup.1 is H and the other is CONH.sub.2, R.sup.2 and R.sup.3 are individually H, methyl, ethyl or n-propyl, and a pharmaceutically-acceptable acid addition salt thereof formed with a non-toxic acid.
- 2. A process according to claim 1 in which dl-3-hydroxy-7-di-n-propylamino-5,6,7,8-tetrahydro-2-naphthalenecarboxamide is the drug administered.
- 3. A process according to claim 1 in which dl-3-hydroxy-7-dimethylamino-5,6,7,8-tetrahydro-2-naphthalenecarboxamide is the drug administered.
- 4. A method of inhibiting the secretion of prolactin in mammals which comprises administering to a mammal having a condition accompanied by excess prolactin secretion and in need of treatment a prolactin secretion inhibiting dose of a drug of the formula ##STR14## wherein one of R and R.sup.1 is H and the other is CONH.sub.2, R.sup.2 and R.sup.3 are individually H, methyl, ethyl or n-propyl, and a pharmaceutically-acceptable acid addition salt thereof formed with a non-toxic acid.
- 5. A process according to claim 4 in which dl-3-hydroxy-7-di-n-propylamino-5,6,7,8-tetrahydro-2-naphthalenecarboxamide is the drug administered.
- 6. A process according to claim 4 in which dl-3-hydroxy-7-dimethylamino-5,6,7,8-tetrahydro-2-naphthalenecarboxamide is the drug administered.
- 7. A method of treating Parkinson's Syndrome which comprises administering to a human suffering from Parkinson's Syndrome and in need of treatment, a dose of a drug of the formula ##STR15## wherein one of R and R.sup.1 is H and the other is CONH.sub.2, R.sup.2 and R.sup.3 are individually H, methyl, ethyl or n-propyl, and a pharmaceutically-acceptable acid addition salts thereof formed with a non-toxic acid effective to alleviate some or all of the manifestations of Parkinson's Syndrome.
- 8. A process according to claim 7 in which dl-3-hydroxy-7-di-n-propylamino-5,6,7,8-tetrahydro-2-naphthalenecarboxamide is the drug administered.
- 9. A process according to claim 7 in which dl-3-hydroxy-7-dimethylamino-5,6,7,8-tetrahydro-2-naphthalenecarboxamide is the drug administered.
- 10. A pharmaceutical formulation in unit dosage form adapted for administration to achieve a dopaminergic effect containing per unit dosage a dopaminergically-effective amount of a drug of the formula U.S. Ser. No. 588,180 ##STR16## wherein one of R and R.sup.1 is H and the other is CONH.sub.2, R.sup.2 and R.sup.3 are individually H, methyl, ethyl or n-propyl, and a pharmaceutically-acceptable acid addition salt thereof formed with a non-toxic acid plus one or more pharmaceutical excipients.
- 11. A formulation according to claim 10 in which dl-3-hydroxy-7-di-n-propylamino-5,6,7,8-tetrahydro-2-naphthalenecarboxamide is the active drug.
- 12. A formulation according to claim 10 in which dl-3-hydroxy-7-dimethylamino-5,6,7,8-tetrahydro-2-naphthalenecarboxamide is the active drug.
Parent Case Info
This application is a division of application Ser. No. 442,074, filed Nov. 16, 1982, now U.S. Pat. No. 4,448,990.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4410519 |
Seiler et al. |
Oct 1983 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
1597140 |
Sep 1981 |
GBX |
Non-Patent Literature Citations (3)
Entry |
Long et al., J. Pharmacology & Exp. Therapeutics, vol. 192, No. 2, pp. 330-342. |
J. Med. Chem., vol. 24, No. 10, 10/81. |
Science, vol. 210, 12/80, pp. 1141-1143. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
442074 |
Nov 1982 |
|